Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
*Pricing may vary based on treatment plan, medication, dose, pharmacy, labs, and follow-up needs
This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
The foundation's Canadian survey found that 51 percent of employers now cover GLP-1 drugs for diabetes alone, down from 56 percent in 2025 and 66 percent in 2024
Hydration cannot be overstated
Phase 3 clinical trials have shown promising weight loss results, and if approved, orforglipron could become the first truly effective oral option in this drug class
Metabolic syndrome is a set of conditions such as elevated blood sugar, blood pressure, and abdominal fat that raises ones risk for cardiac disease and stroke
